Navigation Links
Oncolytics Biotech(R) Inc. Announces Second Quarter 2010 Results
Date:7/29/2010

,578,220) 2,862,509 ----------------------------------------------------------- (9,635,852) (113,568,690) ----------------------------------------------------------- INVESTING ACTIVITIES Capital assets (3,349) (866,566) Purchase of short-term investments - (51,096,801) Redemption of short-term investments 5,846,634 48,998,380 Investment in BCY LifeSciences Inc. - 464,602 Investment in Transition Therapeutics Inc. - 2,532,343 ----------------------------------------------------------- 5,843,285 31,958 ----------------------------------------------------------- FINANCING ACTIVITIES Proceeds from exercise of warrants and stock options 373,085 30,565,278 Proceeds from acquisition of private company 1,800,120 1,800,120 Proceeds from private placements - 38,137,385 Proceeds from public offerings 6,172,819 66,320,777 ----------------------------------------------------------- 8,346,024 136,823,560 ----------------------------------------------------------- (Decrease) increase in cash and cash equivalents during the period 4,553,457 23,286,828 Impact of foreign exchange on cash and cash equivalents - (80,867) ----------------------------------------------------------- Cash and cash equivalents, beginning of the period 7,429,895 - ----------------------------------------------------------- Cash and cash equivalents, end of the period 11,983,352 23,205,961 ----------------------------------------------------------- ---------------------------------
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Issuance of 35th U.S. Patent
2. Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting
3. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
4. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
5. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
6. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
7. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
8. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
9. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
10. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
11. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Bi-Biomics today announced a discovery ... additive. The improvement in histological quality provided the ... in all daughter cells. , After processing with ... analyzed at 1000-1600x using light microscopy. Phylogenetic ... all daughter cells displayed predominant binary features --- ...
(Date:3/5/2015)... and TORONTO , March 5, ... a clinical-stage company developing new therapeutics and molecular diagnostics ... that William G. Rice , Ph.D., Chairman, President ... 27th Annual ROTH Conference on Tuesday, March 10 th ... Carlton, Laguna Niguel, CA. Dr. ...
(Date:3/5/2015)... DUBLIN , Mar. 05, 2015 Research and ... addition of the "Mature Biotech Outlook 2015: New ... to their offering. All biotech companies ... Celgene (CELG), in past year, have given a positive ... These companies have been able to select therapy/niche indication ...
(Date:3/5/2015)... e2b teknologies , a premier Sage ... Ohio, today announced a leading independent multi-specialty physician group ... to the latest version of Sage 100 ERP ... its kind in the region, the organization has an ... efficiency and data accessibility are paramount to their ongoing ...
Breaking Biology Technology:Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2
... Md., Feb. 15, 2011 United Therapeutics Corporation (Nasdaq: ... for the fourth quarter and year ended December 31, 2010. ... by the growth in our revenues," remarked Martine Rothblatt, ... addition, we are pleased to announce that we expect ...
... Reportlinker.com announces that a new market research report ... Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers ... http://www.reportlinker.com/p0386436/Pipeline-Insight-Cancer-Overview--Breast-and-Gynecological-Cancers---Promising-agents-emerge-for-BRCA-positive-patients.html ... types covered in this report are set to ...
... is available in French . Scientists have ... two paintings by Vincent van Gogh and other artists of ... to understanding how to stop the bright yellow colours of ... brown shade, and fading over time. In the meantime, the ...
Cached Biology Technology:United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 2United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 3United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 4United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 5United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 6United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 7United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 8United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results 9Reportlinker Adds Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients 2X-rays show why van Gogh paintings lose their shine 2X-rays show why van Gogh paintings lose their shine 3X-rays show why van Gogh paintings lose their shine 4
(Date:3/3/2015)... LAKE FOREST, Calif. , March 3, ... ("Company"), the leading provider of advanced cryogenic ... serving markets including immunotherapies, stem cells, cell ... health, and reproductive medicine, today announced the ... Hutchinson Cancer Research Centers, ("Fred Hutch") ...
(Date:2/25/2015)... LITTLE ROCK, Ark. , Feb. 25, 2015 ... of software and billing in the Health and ... software as well as to MYiCLUBonline.  The latest ... MYiCLUBonline and the inclusion of cardless check-in via ... demonstrated for the first time through interactive displays ...
(Date:2/23/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... for DISTRIBUTED VOICE DIRECTED PAYMENT METHOD AND ... new groundbreaking payment method. Payment accounts may be selected ... be accessed if both the speech (the word associated ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3
... are essential in the fight against breast cancer. ... system for investigation of physiological and pathological processes ... that occurs during puberty and the alveogenesis processes ... in many tissues during embryogenesis and are also ...
... in a wide variety of cells and tissues, including ... can enter the cytoplasm from the extracellular environment or ... enzymes, other signaling molecules, transcription factors, and cytoskeletal components. ... "Calcium Signaling" explores the channels and pumps that transport ...
... For one species of seabird in the Galpagos, the child abuse ... The new study of Nazca boobies by Wake Forest University ... who are abused when they are young often grow up to ... the ornithology journal, The Auk . "We were ...
Cached Biology News:Child abuse in birds: Study documents 'cycle of violence' in nature 2
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
... Klein Taq is a derivative of Taq ... truncated Thermus aquaticus DNA polymerase. Expressed from ... initiates at Met236, bypassing the 5'-3' exonuclease ... enzyme reveals a highly active and even ...
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
96 Well Base Plate...
Biology Products: